Private Equity
Sugar Land, Texas-based QuVa Pharma, a platform for sterile compounding pharmacy services, has secured up to $40 million in debt and equity funding. The funding includes $15 million from investors that include Bain Capital Private Equity, a $20 million term loan from Silicon Valley Bank and a $5 million lease facility from Farnam Street Financial.
3 min read · 31 January 2018
2 min read · 30 January 2018
Care Advantage, a portfolio company of BelHealth Investment Partners, has acquired Alexandria, Virginia-based Ready Hands Inc, a provider of personal care services for the elderly and disabled. No financial terms were disclosed.
3 min read · 30 January 2018
Redwood City, California-based Armo BioSciences Inc, a late-stage immuno-oncology company has raised about $128 million for its IPO after pricing its over 7.5 million shares at $17 per share. The stock began trading January 26, 2018 on the NASDAQ under the ticker symbol "ARMO." Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp are the lead underwriters. Armo’s pre-IPO backers were Qiming Venture Partners, Decheng Capital, Sequoia Capital, Quan Capital, RTW Investments, Kleiner Perkins Caufield and Byers, OrbiMed, DAG Ventures, NanoDimension, HBM Healthcare Investments and GV.
3 min read · 29 January 2018
Adaptive Health Capital has provided debt financing to Pasadena, California-based GrandCare Health Services, a provider of home healthcare services. No financial terms were disclosed.
3 min read · 29 January 2018
Cambridge, Massachusetts-based Solid Biosciences, which is focused on treating Duchenne muscular dystrophy, has raised $125 million after pricing its IPO of over 7.8 million at $16 per share. The stock began trading January 26, 2018 on the NASDAQ under the ticker symbol “SLDB.” J.P. Morgan, Goldman Sachs and Leerink Partners are the lead underwriters. Solid Biosciences' pre-IPO backers include RA Capital Management, Bain Capital Life Sciences, RTW Investments, Foresite Capital, Cormorant Asset Management LLC, Perceptive Advisors and Janus Capital Management.
3 min read · 26 January 2018
Boston-based ResTORbio Inc, a clinical-stage biopharmaceutical company focused on treating aging-related diseases, has debuted its IPO after pricing its over 5.6 million shares at $15 per share. The stock began trading January 26, 2018 on the NASDAQ under the ticker symbol “TORC." BofA Merrill Lynch, Leerink Partners and Evercore ISI are the lead underwriters. ResTORbio's pre-IPO includes include OrbiMed, Fidelity Management & Research Company, Rock Springs Capital, Quan Capital and Nest Bio.
2 min read · 26 January 2018
Alliance Physical Therapy Partners, which is backed by GPB Capital, has acquired a majority ownership stake in Wisconsin-based Franklin Rehabilitation, a provider of specialized rehabilitation services to patients suffering ailments related to the musculoskeletal and neurological systems. No financial terms were disclosed.
3 min read · 26 January 2018
Equistone Partners has sold Concept Life Sciences to Spectris plc for 163 million pounds. UK-based Concept Life Sciences is a provider of drug discovery, development and analytical services for the life science sector.
3 min read · 26 January 2018
TPG Capital-backed Mediware Information Systems Inc has acquired Missouri-based MEDTranDirect Inc, a provider of software solutions for healthcare revenue cycle management. No financial terms were disclosed.
3 min read · 25 January 2018
